CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on improving cancer immunotherapy by targeting regulatory T-cells that hinder treatment effectiveness. It aims to develop advanced antibody therapies that specifically alter the tumor environment, enhancing patient outcomes while minimizing side effects.
Tumour immune-therapy has made dramatic improvements in recent years, saving the lives of cancer patients who just afew years ago would have been considered untreatable.
It thereby became apparent that one specific type of immune cell,so called regulatory T-cells, critically hampers the efficacy of tumour immune-therapy.
Tumours, however, attract and exploitthe immune-regulatory function of Tregs to dampen local immune responses and to induce local tolerance.In recent years, inhibitors that dire…
UNIVERSIDAD DE NAVARRA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Edinburgh
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Oss
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
